WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000; Not yet tested in other applications.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
Phospho-CHOP (S30) Polyclonal Antibody detects endogenous levels of CHOP protein only when phosphorylated at S30.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):VLsSD
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
19kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from human CHOP around the phosphorylation site of Ser30. AA range:15-64
show all
Specificity:
Phospho-CHOP (S30) Polyclonal Antibody detects endogenous levels of CHOP protein only when phosphorylated at S30.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):VLsSD
show all
Gene Name:
DDIT3
show all
Protein Name:
DNA damage-inducible transcript 3 protein
show all
Other Name:
DDIT3 ;
CHOP ;
CHOP10 ;
GADD153 ;
DNA damage-inducible transcript 3 protein ;
DDIT-3 ;
C/EBP-homologous protein ;
CHOP ;
C/EBP-homologous protein 10 ;
CHOP-10 ;
Growth arrest and DNA damage-inducible protein GADD153
This gene encodes a member of the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors. The protein functions as a dominant-negative inhibitor by forming heterodimers with other C/EBP members, such as C/EBP and LAP (liver activator protein), and preventing their DNA binding activity. The protein is implicated in adipogenesis and erythropoiesis, is activated by endoplasmic reticulum stress, and promotes apoptosis. Fusion of this gene and FUS on chromosome 16 or EWSR1 on chromosome 22 induced by translocation generates chimeric proteins in myxoid liposarcomas or Ewing sarcoma. Multiple alternatively spliced transcript variants encoding two isoforms with different length have been identified. [provided by RefSeq, Aug 2010],
show all
Function:
Disease:A chromosomal aberration involving DDIT3 is found in a form of malignant myxoid liposarcoma [MIM:126337]. Translocation t(12;16)(q13;p11) with FUS.,Function:Inhibits the DNA-binding activity of C/EBP and LAP by forming heterodimers that cannot bind DNA.,similarity:Belongs to the bZIP family.,similarity:Contains 1 bZIP domain.,subunit:Heterodimer.,
show all
Cellular Localization:
Cytoplasm . Nucleus . Present in the cytoplasm under non-stressed conditions and ER stress leads to its nuclear accumulation. .
show all
Tissue Expression:
Muscle,Skeletal muscle,
show all
Research Areas:
>>MAPK signaling pathway ;
>>Protein processing in endoplasmic reticulum ;
>>Apoptosis ;
>>Non-alcoholic fatty liver disease ;
>>Alzheimer disease ;
>>Parkinson disease ;
>>Amyotrophic lateral sclerosis ;
>>Prion disease ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Transcriptional misregulation in cancer ;
>>Lipid and atherosclerosis